Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Designer drugs: new directed therapies for cancer.

Feig SA.

Int J Hematol. 2002 Aug;76 Suppl 2:281-3. Review.

PMID:
12430937
2.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
3.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
4.

Advances in the treatment for haematological malignancies.

Piccaluga PP, Martinelli G, Baccarani M.

Expert Opin Pharmacother. 2006 Apr;7(6):721-32. Review.

PMID:
16556088
5.

Novel anticancer agents in clinical development.

Adjei AA, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S5-15. Review.

PMID:
14508076
6.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
7.

Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.

Ravandi F, Talpaz M, Estrov Z.

Clin Cancer Res. 2003 Feb;9(2):535-50. Review.

8.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
9.
10.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
11.

Importance of molecular computer modeling in anticancer drug development.

Geromichalos GD.

J BUON. 2007 Sep;12 Suppl 1:S101-18. Review.

PMID:
17935268
12.

Developing new drugs for the treatment of lymphoma.

O'Connor OA.

Eur J Haematol Suppl. 2005 Jul;(66):150-8. Review.

PMID:
16007885
13.

Molecular approach to breast cancer treatment.

Yarden Y, Baselga J, Miles D.

Semin Oncol. 2004 Oct;31(5 Suppl 10):6-13. Review.

PMID:
15490369
14.

Multitarget drugs: the present and the future of cancer therapy.

Petrelli A, Valabrega G.

Expert Opin Pharmacother. 2009 Mar;10(4):589-600. doi: 10.1517/14656560902781907 . Review.

PMID:
19284362
15.

New cytotoxic and molecular-targeted therapies of head and neck tumors.

Caponigro F, Ionna F, Comella G.

Curr Opin Oncol. 2004 May;16(3):225-30. Review.

PMID:
15069317
16.

An overview of targeted treatments in cancer.

Abou-Jawde R, Choueiri T, Alemany C, Mekhail T.

Clin Ther. 2003 Aug;25(8):2121-37. Review.

PMID:
14512124
17.

Molecular basis of therapeutic approaches to gastric cancer.

Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D.

J Gastroenterol Hepatol. 2009 Jan;24(1):37-41. doi: 10.1111/j.1440-1746.2008.05753.x. Review.

PMID:
19196394
18.

The biology of non-small-cell lung cancer: identifying new targets for rational therapy.

Rosell R, Felip E, Garcia-Campelo R, BalaƱa C.

Lung Cancer. 2004 Nov;46(2):135-48. Review.

PMID:
15474661
19.

[Targeted therapies in pediatric oncology: a new therapeutic approach?].

Jubert C, Geoerger B, Grill J, Hartmann O, Vassal G.

Arch Pediatr. 2006 Feb;13(2):189-94. Epub 2005 Nov 17. Review. French.

PMID:
16298518
20.

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M.

Clin Colorectal Cancer. 2004 May;4(1):51-62. Review.

PMID:
15207021
Items per page

Supplemental Content

Write to the Help Desk